March 8, 2022
Co-Director, Singapore Translational Cancer Consortium;
Deputy Group Chief Executive Officer (Research & Education) Singapore Health Services;
Deputy Medical Director (Clinical), National Cancer Centre Singapore;
Senior Associate Dean, MD Programme, Duke-NUS Medical School
Professor Lim Soon Thye graduated from the National University of Singapore and subsequently obtained his membership with the Royal College of Physician (UK). He received specialist training in medical oncology at the National Cancer Centre Singapore and further training in lymphoid malignancies at the University of Southern California. Currently, he is a senior consultant and deputy medical director (clinical) at NCCS. He also heads Singhealth-DukeNUS Blood Cancer Centre and a regular rank professor at Duke-NUS medical school.
His other leadership roles and positions include serving as the chairman of the Singhealth Central Institutional Review Board-B, director of ACP Oncology Clinical Service, chairman of the cancer service line development and chairman of the national medical oncology residency advisory committee. Additionally, he is also the current associate Dean for Clinical Education at Duke-NUS medical school. Prof Lim previously served as the president of the Singapore Society of Oncology from 2006 to 2010, and chairman of the chapter of Medical Oncologist, Academy of Medicine Singapore from 2010 to 2014. He is an active council member at the Singapore Cancer Society (SCS) where he also chairs the SCS medical professional and audit committee as well as the cancer treatment fund committee.
Prof Lim’s research focus is on lymphoid malignancies; in particular T and NK/T cell lymphomas, that occur more frequently in Asia. He has published more than 100 papers in high impact international journals such as Cancer Cell, Lancet Oncology and Journal of Clinical Oncology. He is the co-founder of the Asian Lymphoma Study Group, which includes academic medical centres across Asia.
Prof Lim was also the Principal Lead Investigator of a Translational and Clinical Research (TCR) Flagship Programme, Large Collaborative Grant (LCG) funded by NMRC (National Lymphoma Translational Research Program: From Genomics to Therapeutics from 2014 to 2019; Singapore lYMPHhoma TranslatiONal studY from 2019-2024).
Additionally, his team leads the blood cancer (T cell lymphoma) genomics project at the International Cancer Genomics Consortium. His group has been successful in securing more than S$20 million of NMRC, industrial and philanthropic funding over the years. His research efforts won him the 3rd Kobayashi Foundation Award in May 2014 in Taipei. This award was created to recognize distinguished research achievements in the field of cancer in Asian countries. Previously, he was also awarded Singhealth Distinguished Young leader Award in 2011. In 2015, he is also conferred the title of Tanoto Professorship in Medical Oncology. More recently, he is also part of an international team that won the American Association of Cancer Research (AACR) Team Science Award. The AACR Team Award is a prestigious award that recognizes an outstanding interdisciplinary research team for its innovative and meritorious science that advances our fundamental knowledge of cancer.
SINGAPORE, 7 July 2022 – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company, whose mission is to save and improve lives through early, actionable, and personalized diagnoses with its innovative RNA-powered cancer early detection solutions, announced today the signing of a Memorandum of Understanding (MOU) that launched Project CADENCE (CAncer Detected Early caN be CurEd). Project CADENCE is the world’s first large-scale clinical research project for the discovery and validation of novel combinations blood-borne circulating microRNA (miRNA) and DNA methylation biomarkers that will lead to the development of a multi-cancer early detection test for up to nine high incidence and high mortality cancers, including lung, breast, colorectal, liver, stomach (gastric), esophageal, ovarian, pancreatic, and prostate cancers.
A new national consortium – the Consortium for Clinical Research and Innovation, Singapore (CRIS) – has been officially launched by the Minister for Health Mr Ong Ye Kung on 6 April 2022 CRIS brings together five key national R&D, clinical translation and service initiatives that will advance clinical research and innovation for Singapore, and establish important capabilities for a future-ready healthcare system